Verici Dx (LON:VRCI) Stock Price Down 16% – Should You Sell?

Verici Dx plc (LON:VRCIGet Free Report)’s stock price was down 16% during mid-day trading on Tuesday . The stock traded as low as GBX 0.20 and last traded at GBX 0.21. 720,676 shares changed hands during mid-day trading, a decline of 59% from the average session volume of 1,758,664 shares. The stock had previously closed at GBX 0.25.

Verici Dx Stock Performance

The company has a debt-to-equity ratio of 3.03, a current ratio of 3.94 and a quick ratio of 8.49. The stock has a 50-day moving average price of GBX 0.32 and a 200-day moving average price of GBX 0.46. The company has a market capitalization of £4.80 million, a price-to-earnings ratio of -0.23 and a beta of 1.26.

Verici Dx Company Profile

(Get Free Report)

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.

Further Reading

Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.